Latest News for: myeloid cell

Edit

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, ...

Nasdaq Globe Newswire 20 Mar 2025
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline ... .
Edit

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline (Form 6-K) (Sanofi SA)

Public Technologies 20 Mar 2025
Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline • ... myeloid cells to induce deep B-cell depletion via targeted phagocytosis.
Edit

Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline (Sanofi SA)

Public Technologies 20 Mar 2025
DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis.
Edit

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College ...

Victoria Advocate 19 Mar 2025
- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning ....
Edit

NK Cell Therapy Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, ...

GetNews 17 Mar 2025
"NK Cell Therapy Market" ... NK Cell Therapy Market Dynamics ... NK cells present immense potential as innovative therapeutic agents against various diseases, including HER2-positive solid tumors, B-cell lymphoma, acute myeloid leukemia, and more.
Edit

Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

ACCESSWIRE 17 Mar 2025
... the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.
Edit

Why India lags in making cancer treatment affordable

Hindustan Times 15 Mar 2025
Now, CAR T-cell therapy is like fitting the immune system with high-tech goggles so it can spot the enemy ... Through his ventures, Vor Biopharma and Myeloid Therapeutics, he has been exploring ways to make cell therapy more accessible.
Edit

Next-gen cancer research: Canadian Cancer Society invests in the future of cancer detection and treatment

Canoe 13 Mar 2025
Tracking cancer cell changes in real-time by making them glow ... This project is testing a system to deliver engineered immune cells that recognize and target genes that are only present in acute myeloid leukemia cells.
Edit

Mapping the Shift from Healthy Stem Cells to Oral Cancer

The Scientist 12 Mar 2025
To their surprise, they found that TI cells recruited myeloid immune cells to the tumor microenvironment ... aberrant proliferation and led to the recruitment of myeloid cells to aid tissue infiltration.
Edit

Hemogenyx Pharmaceuticals PLC Announces Institutional Investment

ACCESSWIRE 11 Mar 2025
... continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ("R/R AML").
Edit

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, ...

ACCESSWIRE 11 Mar 2025
Leveraging its discovery of the central role the Delta Opioid Receptor plays in modulating the immunosuppressive effects of myeloid derived suppressor cells (MDSCs) and tumor associated M2 polarized ...
Edit

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

ACCESSWIRE 10 Mar 2025
Leveraging its discovery of the central role the Delta Opioid Receptor plays in modulating the immunosuppressive effects of myeloid derived suppressor cells (MDSCs) and tumor associated M2 polarized ...
Edit

Chronic Myeloid Leukemia Market Expected to Experience Major Growth by 2032, According to DelveInsight | ...

GetNews 07 Mar 2025
It is characterized by the uncontrolled growth of immature myeloid cells, which are a type of white blood cells ... BCR-ABL1, which produces a protein that promotes the excessive growth of myeloid cells.
Edit

High-paying jobs linked to CANCER... do you work in one of them? | Daily Mail Online

The Daily Mail 07 Mar 2025
Apart from this, prolonged exposure to radiation can also cause blood cancers such as osteosarcoma - bone cancer - and acute myeloid leukemia - cancer of the bone marrow, where blood cells are produced.
Edit

Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, ...

GetNews 06 Mar 2025
TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment.
×